Related Experiment Video

Updated: Jun 26, 2026

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

Targeted use of Prostaglandin E1 Therapy in "Duct-dependent" Congenital Diaphragmatic Hernia

Dana Levinkopf1, Abhijit Bhattacharya1, David Healy1

  • 1Department of Neonatology, Royal Hospital for Children, Glasgow UK.

American Journal of Respiratory and Critical Care Medicine
|June 25, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Transuterine Fetal Tracheal Occlusion Model in Mice06:31

Transuterine Fetal Tracheal Occlusion Model in Mice

Published on: February 5, 2021

Continuous Telemetric In Utero Tracheal Pressure Measurements in Fetal Lambs05:40

Continuous Telemetric In Utero Tracheal Pressure Measurements in Fetal Lambs

Published on: December 22, 2023

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...